Oa10 Check Mate 078: Patient-Reported Outcomes (Pros) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (Nsclc)
Wu, Y.; Chang, J.; Zhang, L.; Tu, H.; Wu, L.; Feng, J.; Lu, S.; Zhou, C.; Wang, J.; Mok, T.; Taylor, F.; Mossman, B.; Penrod, J.; Lawrance, R.; Blum, S.
Journal of Thoracic Oncology 13(12): S1047-S1048
2018
ISSN/ISBN: 1556-0864
DOI: 10.1016/j.jtho.2018.10.020
Accession: 067002466
PDF emailed within 0-6 h: $19.90
Related References
Vokes, E.E.; Ready, N.; Felip, E.; Horn, L.; Burgio, M.A.; Antonia, S.J.; Arén Frontera, O.; Gettinger, S.; Holgado, E.; Spigel, D.; Waterhouse, D.; Domine, M.; Garassino, M.; Chow, L.Q.M.; Blumenschein, G.; Barlesi, F.; Coudert, B.; Gainor, J.; Arrieta, O.; Brahmer, J.; Butts, C.; Steins, M.; Geese, W.J.; Li, A.; Healey, D.; Crinò, L. 2018: Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases Annals of Oncology: Official Journal of the European Society for Medical Oncology 29(4): 959-965Bordoni, R.; Ciardiello, F.; Von Pawel, J.; Cortinovis, D.; He, P.; Karagiannis, T.; Ballinger, M.; Sandler, A.; Yu, W.; Felizzi, F.; Rittmeyer, A. 2017: P1.01-052 Patient-Reported Outcomes (Pros) in Oak: A Phase Iii Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (Nsclc) Journal of Thoracic Oncology 12(11): S1914-S1915
Horn, L.; Spigel, D.R.; Vokes, E.E.; Holgado, E.; Ready, N.; Steins, M.; Poddubskaya, E.; Borghaei, H.; Felip, E.; Paz-Ares, L.; Pluzanski, A.; Reckamp, K.L.; Burgio, M.A.; Kohlhäeufl, M.; Waterhouse, D.; Barlesi, F.; Antonia, S.; Arrieta, O.; Fayette, J.ér.ôm.; Crinò, L.; Rizvi, N.; Reck, M.; Hellmann, M.D.; Geese, W.J.; Li, A.; Blackwood-Chirchir, A.; Healey, D.; Brahmer, J.; Eberhardt, W.E.E. 2017: Nivolumab Versus Docetaxel in Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes from two Randomized, Open-Label, Phase IIi Trials (CheckMate 017 and CheckMate 057) Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 35(35): 3924-3933
Peters, S.; Shaw, A.T.; Besse, B.; Felip, E.; Solomon, B.J.; Soo, R.A.; Bearz, A.; Gadgee, S.M.; Lin, C-C.; Kao, S.; Seto, T.; Masters, E.T.; Abbattista, A.; Clancy, J.S.; Thurm, H.; Reisman, A.; Camidge, D.R. 2018: Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC) Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii504-Viii505
Reck, M.; Schenker, M.; Lee, K.Hyeong.; Provencio, M.; Nishio, M.; Lesniewski-Kmak, K.; Sangha, R.; Ahmed, S.; Raimbourg, J.; Feeney, K.; Corre, R.; Franke, F.Andre.; Richardet, E.; Penrod, J.R.; Yuan, Y.; Nathan, F.E.; Bhagavatheeswaran, P.; DeRosa, M.; Taylor, F.; Lawrance, R.; Brahmer, J. 2019: Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial European Journal of Cancer 116: 137-147
Lu, S.; Wang, J.; Cheng, Y.; Mok, T.; Chang, J.; Zhang, L.; Feng, J.; Tu, H.-Y.; Wu, L.; Zhang, Y.; Luft, A.; Zhou, J.-Y.; Ma, Z.; Lu, Y.; Hu, C.; Shi, Y.; Ying, K.; Zhong, H.; Poddubskaya, E.; Soo, R.A.; Chia, Y.H.; Li, A.; Li, A.; Wu, Y.-L. 2021: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078) Lung Cancer 152: 7-14
Harris, R.; Reinmuth, N.; Mitchell, P.; Zhu, J.; Chang, I.F.; Pichon, E. 2017: P3.02c-040 Checkmate 384: A Phase 3B/4 Dose-Frequency Optimization Trial of Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (Nsclc) Journal of Thoracic Oncology 12(1): S1298-S1299
Borghaei, H.; Gettinger, S.; Vokes, E.E.; Chow, L.Q.M.; Burgio, M.A.; de Castro Carpeno, J.; Pluzanski, A.; Arrieta, O.; Frontera, O.A.én.; Chiari, R.; Butts, C.; Wójcik-Tomaszewska, J.; Coudert, B.; Garassino, M.C.; Ready, N.; Felip, E.; García, M.A.; Waterhouse, D.; Domine, M.; Barlesi, F.; Antonia, S.; Wohlleber, M.; Gerber, D.E.; Czyzewicz, G.; Spigel, D.R.; Crino, L.; Eberhardt, W.E.E.; Li, A.; Marimuthu, S.; Brahmer, J. 2021: Five-Year Outcomes from the Randomized, Phase IIi Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 39(7): 723-733
Reck, M.; Brahmer, J.; Bennett, B.; Taylor, F.; Penrod, J.R.; DeRosa, M.; Dastani, H.; Spigel, D.R.; Gralla, R.J. 2018: Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057 European Journal of Cancer 102: 23-30
Perol, M.; Peters, S.; Pavlakis, N.; Levchenko, E.; Platania, M.; Oliveira, J.; Novello, S.; Karagiannis, T.; Zeaiter, A.; Dziadziuszko, R. 2018: 138Pd_Pr Patient-reported outcomes (Pros) in Alex: A phase Iii study of alectinib (Alec) vs crizotinib (Criz) in non-small-cell lung cancer (Nsclc) Journal of Thoracic Oncology 13(4): S80-S81
Reck, M.; Taylor, F.; Penrod, J.R.; DeRosa, M.; Morrissey, L.; Dastani, H.; Orsini, L.; Gralla, R.J. 2018: Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 13(2): 194-204
Spigel, D.R.; McCleod, M.; Jotte, R.M.; Einhorn, L.; Horn, L.; Waterhouse, D.M.; Creelan, B.; Babu, S.; Leighl, N.B.; Chandler, J.C.; Couture, F.; Keogh, G.; Goss, G.; Daniel, D.B.; Garon, E.B.; Schwartzberg, L.S.; Sen, R.; Korytowsky, B.; Li, A.; Aanur, N.; Hussein, M.A. 2019: Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153) Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 14(9): 1628-1639
Bordoni, R.; Ciardiello, F.; von Pawel, J.; Cortinovis, D.; Karagiannis, T.; Ballinger, M.; Sandler, A.; Yu, W.; He, P.; Matheny, C.; Felizzi, F.; Rittmeyer, A. 2018: Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer Clinical Lung Cancer 19(5): 441-449.E4
Ready, N.; Hellmann, M.D.; Awad, M.M.; Otterson, G.A.; Gutierrez, M.; Gainor, J.F.; Borghaei, H.; Jolivet, J.; Horn, L.; Mates, M.; Brahmer, J.; Rabinowitz, I.; Reddy, P.S.; Chesney, J.; Orcutt, J.; Spigel, D.R.; Reck, M.; O'Byrne, K.John.; Paz-Ares, L.; Hu, W.; Zerba, K.; Li, X.; Lestini, B.; Geese, W.J.; Szustakowski, J.D.; Green, G.; Chang, H.; Ramalingam, S.S. 2019: First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 37(12): 992-1000
Wu, Y.-L.; Lu, S.; Cheng, Y.; Zhou, C.; Wang, J.; Mok, T.; Zhang, L.; Tu, H.-Y.; Wu, L.; Feng, J.; Zhang, Y.; Luft, A.V.; Zhou, J.; Ma, Z.; Lu, Y.; Hu, C.; Shi, Y.; Baudelet, C.; Cai, J.; Chang, J. 2019: Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population with Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase IIi Clinical Trial Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 14(5): 867-875